Search
for
Sort by
Research 151–180 of 1000+
- Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
- Efficacy and Safety of Thermobalancing Therapy in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia was Confirmed by Clinical Trial
- Efficacy and safety of tofacitinib in patients with alopecia areata
- Efficacy and Safety of Spironolactone in Acne Management
- Anabolic-androgenic steroids and cardiovascular risk
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- ORAL MINOXIDIL EFFICACY AND SAFETY IN MALE ANDROGENETIC ALOPECIA - A LITERATURE REVIEW
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Parents May Over-report Use of Home Safety Interventions
- Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
- Cardiodermatology: the heart of the connection between the skin and cardiovascular disease
- A Comprehensive Narrative Review Designed to Evaluate the Health Benefits of Apples and Their Derivatives, with a Focus on Cardiovascular Disease (CVD) Prevention, Metabolic Regulation, and Chronic Disease Mitigation
- Comprehensive Administrative and Engineering Strategies for Radiation Protection and Occupational Health Safety
- Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Efectos de la disminución de los depósitos tisulares de hierro sobre los factores de riesgo cardiovascular en pacientes con hiperandrogenismo ovárico funcional
- A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia
- NAD⁺ Biology in Ageing and Chronic Disease: Mechanisms and Evidence across Skin, Fertility, Osteoarthritis, Hearing and Vision Loss, Gut Health, Cardiovascular–Hepatic Metabolism, Neurological Disorders, and Muscle
- Safety and tolerability of low dose oral minoxidil monotherapy in female pattern hair loss: A retrospective review with longitudinal ambulatory blood pressure monitoring
- Hormone therapy for transgender patients
- Nutritional management in women with polycystic ovary syndrome: A review study
- Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia